ArticleMicroorganisms2021
A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.
Open access · goldAbstract read
In one paragraph
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials.Viruses · 2023Pooled it
- Trial
- Article
- Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2023Article
- COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.Clinical microbiology reviews · 2022Review
- Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection.Infectious diseases and therapy · 2022Article
- The Effectiveness of Convalescent Plasma for the Treatment of Novel Corona Virus Disease 2019: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Article
- Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 7 institutions in 2 countries.
Vasiliki PappaHematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.
Anthi BouchlaHematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.
Evangelos TerposDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-5133-1422
Thomas P ThomopoulosHematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.
Margherita RosatiHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
Dimitris StellasHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.ORCID 0000-0002-7787-3921
Anastasia AntoniadouFourth Department of Internal Medicine, University General Hospital "Attikon", School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Andreas MentisNational Influenza Reference Laboratory of Southern Greece, Hellenic Pasteur Institute, 11521 Athens, Greece.
Sotirios G PapageorgiouHematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.ORCID 0000-0002-3376-837X
Marianna PolitouHematology Laboratory-Blood Bank, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Anastasia KotanidouFirst Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-2508-500X
Ioannis KalomenidisFirst Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-9729-3492
Garyfalia Poulakou3rd Department of Internal Medicine, Sotiria General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Edison JahajFirst Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-7306-713X
Eleni KorompokiDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0003-0403-8316
Sotiria GrigoropoulouFourth Department of Internal Medicine, University General Hospital "Attikon", School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Xintao HuHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-6552-9357
Jenifer BearHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Sevasti KaraliotaHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
Robert BurnsHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Maria PagoniHaematology-Lymphomas Department and BMT Unit, Evangelismos Hospital, 10676 Athens, Greece.
Ioannis Trontzas3rd Department of Internal Medicine, Sotiria General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Elisavet GrouziTransfusion Service and Clinical Hemostasis of Saint Savvas, Oncology Hospital of Athens, 11522 Athens, Greece.
Stavroula LabropoulouNational Influenza Reference Laboratory of Southern Greece, Hellenic Pasteur Institute, 11521 Athens, Greece.
Kostantinos StamoulisHellenic National Blood Transfusion Center, 13678 Athens, Greece.
Aristotelis BamiasHematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.ORCID 0000-0002-5996-7262
Sotirios TsiodrasFourth Department of Internal Medicine, University General Hospital "Attikon", School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Barbara K FelberHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
George N PavlakisHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
Meletios- Athanasios DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-8990-3254
National and Kapodistrian University of Athens · GRNational Cancer Institute · USPasteur Hellenic Institute · GREvangelismos Hospital · GRFrederick National Laboratory for Cancer Research · USNational Hellenic Research Foundation · GRSt Savas Hospital · GR
Funding
COVID-19 vaccine in naive individuals and cancer patientsZIABC011940 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2020 to 2024
$3.7MCOVID-19 vaccine developmentZIABC011939 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2020 to 2022
$2.0MNCI NIH HHS No grant.SYNENOSIS No grant.
Abstract
COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To evaluate the efficacy of CP, a matched propensity score analysis was used comparing the intervention (
Indexed as
convalescent plasmaCOVID-19efficacySARS-CoV-2 antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.